KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Operating Income: 2009-2024

Historic Operating Income for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $230.8 million.

  • Acadia Pharmaceuticals' Operating Income rose 12.99% to $35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.9 million, marking a year-over-year increase of 114.66%. This contributed to the annual value of $230.8 million for FY2024, which is 414.52% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Operating Income of $230.8 million as of FY2024, which was up 414.52% from -$73.4 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Operating Income registered a high of $230.8 million during FY2024, and its lowest value of -$286.6 million during FY2020.
  • Its 3-year average for Operating Income is -$22.1 million, with a median of -$73.4 million in 2023.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Operating Income tumbled by 31.19% in 2022 and then skyrocketed by 414.52% in 2024.
  • Yearly analysis of 5 years shows Acadia Pharmaceuticals' Operating Income stood at -$286.6 million in 2020, then soared by 40.53% to -$170.4 million in 2021, then tumbled by 31.19% to -$223.6 million in 2022, then skyrocketed by 67.18% to -$73.4 million in 2023, then surged by 414.52% to $230.8 million in 2024.